Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-γ

Diabetes

Volumn 48, Issue 2, 1999, Pages 254-260

  Wang, Minghan ^a   Wise, Scott C ^a   Leff, Todd ^a   Su, Ti Zhi ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; LANOSTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; STEROL; TROGLITAZONE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CHO CELL; CHOLESTEROL SYNTHESIS; CONCENTRATION (PARAMETERS); DOSE RESPONSE; DRUG BINDING; DRUG MECHANISM; NONHUMAN; PRIORITY JOURNAL;

3T3 CELLS; ANIMALS; ANTICHOLESTEREMIC AGENTS; CELL LINE; CHO CELLS; CHOLESTEROL; CHROMANS; CRICETINAE; CYCLOHEXIMIDE; DACTINOMYCIN; HYPOGLYCEMIC AGENTS; MICE; NUCLEIC ACID SYNTHESIS INHIBITORS; PROTEIN SYNTHESIS INHIBITORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0033047376     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.2.254     Document Type: Article

References (50)

1. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
2. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Wilson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR-γ). J Biol Chem 270:12953-12956, 1995
3. Schoonjans K, Staels B, Auwerx J: Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37:907-925, 1996
4. Lemberger T, Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Ann Rev Cell Dev Biol 12:335-363, 1996
5. 2 is a ligand for the adipocyte determination factor PPAR-γ. Cell 83:803-812, 1995
6. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83:813-819, 1995
7. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR-γ2, a lipid-activated transcription factor. Cell 79:1147-1156, 1994
8. Tai TAC, Jennermann C, Brown KK, Oliver BB, MacGinnitie MA, Wilkison WO, Brown HR, Lehmann JM, Kliewer SA, Morris DC, Graves RA: Activation of the nuclear receptor peroxisome proliferator-activated receptor gamma promotes brown adipocyte differentiation. J Biol Chem 271:29909-29914, 1996
9. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM, Morris DC: Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 50:1087-1094, 1996
10. Lambe KG, Tugwood JD: A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem 239:1-7, 1996
11. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CDM, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A 94:237-241, 1997
12. Hollenberg AN, Susulic VS, Madura JP, Zhang B, Moller DE, Tontonoz P, Sarraf P, Spiegelman BM, Lowell BB: Functional antagonism between CCAAT/enhancer binding protein-alpha and peroxisome proliferator-activated receptor-gamma on the leptin promoter. J Biol Chem 272:5283-5290, 1997
13. De Vos P, Lefebvre AM, Miller SG, Guerre Millo M, Wong K, Saladin R, Hamann LG, Staels B, Briggs MR, Auwerx J: Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma J Clin Invest 98:1004-1009, 1996
14. Kallen CB, Lazar MA: Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A 93:5793-5796, 1996
15. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J: PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15:5336-5348, 1996
16. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668, 1996
17. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD: Thiazolidinediones produce a conformational change in peroxisomal praliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137:4189-4195, 1996
18. Tafuri SR: Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes. Endocrinology 137:4706-4712, 1996
19. Su T-Z, Wang M, Oxender DL, Saltiel AR: Troglitazone increases system A amino acid transport in 3T3-L1 cells. Endocrinology 139:832-837, 1998
20. Fulgencio J-P, Kohl C, Girard J, Pegorier J-P: Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 45:1556-1562, 1996
21. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabet Med 13:365-370, 1996
22. Kumar S, Boulton AJM, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P: Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39:701-709, 1996
23. Onuma T, Tsutsui M, Goto T, Boku A, Takebe K: The effect of a new oral hypoglycemic drug, CS-045, on glucose tolerance and serum lipids in nonobese Japanese patients with non-insulin-dependent diabetes mellitus: a pilot study. Curr Ther Res 55:416-421, 1994
24. Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N, Kobayashi K, Masakado M, Sako Y, Nawata H: Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 11:685-691, 1994
25. Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H, Okuno A, Wada M, Fujiwara T, Horikoshi H: Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42:75-80, 1993
26. Stevenson RW, Hutson NJ, Krupp MN, Volkman RA, Holland GF, Eggler JF, Clark DA, McPherson RK, Hall KL, Danbury BH, Gibbs EM, Kreutter DK: Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice. Diabetes: 39:1218-1227, 1990
27. Stevenson RW, McPherson RK, Genereux PE, Danbury BH, Kreutter DK: Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism 40:1268-1274, 1991
28. Fujita T, Sugiyama Y, Taketomi S, Sohda T, Kawamatsu Y, Iwatsuka H, Suzuoki Z: Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 32:804-810, 1983
29. Colca JR, Dailey CF, Palazuk BJ, Hillman RM, Dinli DM, Melchior GW, Spilman CH: Pioglitazone hydrochloride inhibits cholesterol absorption and lowers plasma cholesterol concentrations in cholesterol-fed rats. Diabetes 40:1669-1674, 1901
30. Brown MS, Faust JR, Goldstein JL, Kaneko I, Endo A: Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblaste incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 253:1121-1128, 1978
31. Metherall JE. Waugh K, Li H: Progesterone inhibits cholesterol biosynthesis in cultured cells. Accumulation of cholesterol precursors. J Biol Chem 271:2627-2633, 1996
32. Zlokarnik G, Negulescu PA, Knapp TE, Mere L, Burres N, Feng L, Whitney M, Roemer K, Tsien RY: Quantitation of transcription and clonal selection of single living cells with β-lactamase as reporter. Science 279:84-88, 1998
33. El-Kebbi IM, Roser S, Pollet RJ: Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism 43:953-958, 1994
34. Castle CK, Colca JR, Melchior GW: Lipoprotein profile characterization of the KKA(y) mouse, a rodent model of type n diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone. Arterioscler Thromb 13:302-309, 1992
35. Hiroyoshi H, YoshiokaT, Kawasaki T, Nakamura K, Matsunuma N, Yamaguchi Y, Sasahara K: Troglitazone (CS-045), a new antidiabetic drug. Annu Rep Sankyo Res Lab 46:1-57, 1994
36. Kreutter DK, Andrews KM, Gibbs EM, Hutson NJ, Stevenson RW: Insulinlike activity of new antidiabetic agent CP 68722 in 3T3-L1 adipocytes. Diabetes 39:1414-1419, 1990
37. Lenhard JM, Kliewer SA, Paulik MA, Plunket KD, Lehmann JM, Weiel JE: Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem Pharmacol 54:801-808, 1997
38. Ciaraldi TP, Huber-Knudsen K, Hickman M, Olefsky JM: Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism 44:976-982, 1995
39. Murano K, Inoue Y, Emoto M, Kaku K, Kaneko T: CS-045, a new oral antidiabetic agent, stimulates fructose-2,6-bisphosphate production in rat hepatocytes. Eur J Pharmacol 254:257-262, 1994
40. Ibrahimi A, Teboul L, Gaillard D, Amri EZ, Ailhaud G, Young P, Cawthome MA, Grimaldi PA: Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol 46:1070-1076, 1994
41. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA: In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39:1056-1062, 1990
42. Cominacini L, Garbin U, Pastorino AM, Campagnola M, Fratta Pasini A, Davoli A, Rigoni A, Lo Cascio V: Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells. Diabetologia 40:165-172, 1997
43. Inoue I, Katayama S, Takahashi K, Negishi K, Miyazaki T, Sonoda M, Komoda T: Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun 235:113-116, 1997
44. Zhang B, Berger J, Zhou G, Elbrecht A, Biswas S, White-Carrington S, Sza-Ikowski D, Moller DE: Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor. J Biol Chem 271:31771-31774, 1996
45. Debiy P, Nash EA, Neklason DW, Metherall JE: Role of multidrug resistance P-glycoproteins in cholesterol esterification. J Biol Chem 272:1026-1031, 1997
46. Lange Y, Steck TL: Cholesterol homeostasis. Modulation by amphiphiles. J Biol Chem 269:29371-29374, 1994
47. Lange Y: Cholesterol movement from plasma membrane to rough endoplasmic reticulum. Inhibition by progesterone. J Biol Chem 269:3411-3414, 1994
48. Metherall JE, Li H, Waugh K: Role of multidrug resistance P-glycoproteins in cholesterol biosynthesis. J Biol Chem 271:2634-2640, 1996
49. Juranka PF, Zastawny RL, Ling V: P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3:2583-2592, 1989
50. Lange Y, Duan H, Mazzone T: Cholesterol homeostasis is modulated by amphiphiles at transcriptional and post-transcriptional loci. J Lipid Res 37:534-539, 1996